This website is for informational purposes only and does not constitute medical advice. Read disclaimer
PE-22-28
A synthetic heptapeptide derived from the sortilin propeptide that acts as a TREK-1 potassium channel blocker, studied as a rapid-acting antidepressant with fewer side effects than traditional antidepressants.
Overview
PE-22-28 is a synthetic heptapeptide (seven amino acids) derived from a fragment of the propeptide of sortilin, a neuronal receptor involved in neurotrophic factor signaling. It was developed through research at the Institut de Pharmacologie Moleculaire et Cellulaire (IPMC) in France, building on the discovery that spadin, a natural peptide released during sortilin processing, acts as a blocker of the TREK-1 potassium channel. PE-22-28 represents a more stable and potent synthetic analog of the active region of spadin.
TREK-1 is a two-pore domain potassium channel expressed in the brain that has emerged as a promising target for antidepressant drug development. Knockout mice lacking the TREK-1 gene display a depression-resistant phenotype, behaving as if they were on chronic antidepressant treatment. This discovery made TREK-1 an attractive target, and blocking this channel with peptides like spadin and PE-22-28 has shown antidepressant-like effects in animal behavioral models.
Research on PE-22-28 has demonstrated several promising characteristics. In animal models of depression (forced swim test, tail suspension test, chronic mild stress model), PE-22-28 showed antidepressant-like effects with a rapid onset of action — effects were observed within 4 days compared to the 2-4 weeks typically required for SSRI antidepressants. The peptide also showed anxiolytic effects without sedation, motor impairment, or the sexual dysfunction commonly associated with SSRI treatment.
PE-22-28 has gained attention in the peptide research community for its novel mechanism of action and rapid antidepressant onset. The concept of targeting ion channels rather than monoamine systems for depression treatment represents a paradigm shift in antidepressant pharmacology. However, the research is still in preclinical stages, and no human clinical trials have been conducted. The peptide's short half-life and need for parenteral administration present pharmacological challenges that would need to be addressed for clinical development.